Lv1
52 积分 2023-07-14 加入
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
3天前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
3天前
求助中
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
3天前
已完结
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
4天前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
4天前
已完结
Prevalence and Consequences of a Delayed Diagnosis in Multiple Myeloma: A Single Institution Experience
7天前
已完结
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
1个月前
已完结
MSR60 Modeling Challenges for Cancer Drugs With Unprecedented Outcomes: Lorlatinib in the First Line Setting of ALK+ aNSCLS As a Case Study
1个月前
已关闭
Distinct size and spatial distribution patterns of ALK-inhibitor-naïve versus ALK-inhibitor exposed ALK-positive NSCLC brain metastases
2个月前
已完结
Beyond ALK fusion positivity: structural complexity as a prognostic indicator in first-line ALK-TKI therapy
2个月前
已完结
皖公网安备34019202002308
